CN1155904A - Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 - Google Patents
Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 Download PDFInfo
- Publication number
- CN1155904A CN1155904A CN95193718A CN95193718A CN1155904A CN 1155904 A CN1155904 A CN 1155904A CN 95193718 A CN95193718 A CN 95193718A CN 95193718 A CN95193718 A CN 95193718A CN 1155904 A CN1155904 A CN 1155904A
- Authority
- CN
- China
- Prior art keywords
- lag
- pro
- ala
- cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000017578 LAG3 Human genes 0.000 title claims abstract description 136
- 101150030213 Lag3 gene Proteins 0.000 title claims abstract description 136
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 30
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 18
- 230000001225 therapeutic effect Effects 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title description 4
- 230000003302 anti-idiotype Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims description 105
- 108060003951 Immunoglobulin Proteins 0.000 claims description 25
- 102000018358 immunoglobulin Human genes 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 18
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 10
- 238000005336 cracking Methods 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 7
- 210000001672 ovary Anatomy 0.000 claims description 7
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 6
- 231100000135 cytotoxicity Toxicity 0.000 claims description 6
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 23
- 239000003446 ligand Substances 0.000 abstract description 2
- 101100063069 Caenorhabditis elegans deg-1 gene Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 58
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 53
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 53
- 230000035931 haemagglutination Effects 0.000 description 49
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 31
- 230000000694 effects Effects 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000000612 antigen-presenting cell Anatomy 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 8
- 230000007503 antigenic stimulation Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 6
- 108020001096 dihydrofolate reductase Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 229960003983 diphtheria toxoid Drugs 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 230000001885 phytohemagglutinin Effects 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 2
- 108700038332 Histone deacetylase 11 Proteins 0.000 description 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 241000173347 Tonsilla Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- XZKAKQROJCKAOP-YWZUXTQFSA-N p20 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 XZKAKQROJCKAOP-YWZUXTQFSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
用于DNA扩增的引物 | 所得到的与亚片段Ig融合的编码亚片段 |
引物(5’)5′GCGCCTCGAGGCCCAGACCATAGGAGAGATGT3′偶联位点 未翻译的5’序列 翻译起点引物(3’)5′GCGCAGATCTCTCCAGACCCAGAACAGTGAGGTTATACAT3′BglII D2结束偶联位点 | LAG-3 D1D2从前导序列到氨基酸241 |
引物(5’)与LAG-3 D1D2相同引物(3’)5′GCGCAGATCTACCTGGGCTAGACAGCTCTGTGAA3′BglII D4结束偶联位点 | LAG-3 D1-D4从前导序列到氨基酸412 |
用于DNA扩增的引物 | 所得到的编码亚片段 |
引物(5’)5′CGCCGTCGACCGCTGCCCAGACCATAGGAGAGATGTG3′SalI偶联位点 未翻译的5’序列 翻译的起点引物(3’)5′GCGCGTCGACTTACATCGAGGCCTGGCCCAGCGCAG3′SalI D1结束偶联位点 | LAG-3 D1从前导序列到氨基酸149 |
引物(5’)与LAG-3D1相同引物(3’)5′GCGCGTCGACTTAACCCAGAACAGTGAGGTTATAC3′SalI D2结束偶联位点 | LAG-3 D1D2从前导序列到氨基酸239 |
引物(5’)与LAG-3D1相同引物(3’)5′GCGCGTCGACTTAACCTGGGCTAGACAGCTCTGTG3 ′SalI D4结束偶联位点 | LAG-3 D1-D4从前导序列到氨基酸412 |
反应物 | 检测 | 平均荧光 | 结论 |
… | GAH-FITC | 0.3 | GAH不干扰 |
二聚体LAG-3D1D4Ig | GAH-FITC | 20.8 | CHO/LAG-3 D1D2的结合抑制二聚体LAG-3 D1D4Ig的结合(58%) |
CHO/LAG-3D1D2,然后二聚体LAG-3D1D4Ig | GAH-FITC | 8.5 | |
单聚体LAG-3D1D2Ig | GAH-FITC | 62.5 | CHO/LAG-3 D1D2的结合抑制单聚体LAG-3 D1D2Ig的结合(27%) |
CHO/LAG-3D1D2,然后单聚体LAG-3D1D2Ig | GAH-FITC | 10.9 |
-22Met-Trp-Glu-Ala-Gln-Phe-Leu-Gly-Leu-Leu-Phe-Leu-Gln-Pro-Leu- |
Trp-Val-Ala-Pro-Val-Lys-Pro |
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9405643 | 1994-05-06 | ||
FR94/05643 | 1994-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1155904A true CN1155904A (zh) | 1997-07-30 |
CN1110557C CN1110557C (zh) | 2003-06-04 |
Family
ID=9463004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95193718A Expired - Lifetime CN1110557C (zh) | 1994-05-06 | 1995-05-05 | Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 |
Country Status (18)
Country | Link |
---|---|
US (3) | US5955300A (zh) |
EP (1) | EP0758383B1 (zh) |
JP (1) | JP3700859B2 (zh) |
KR (1) | KR100257466B1 (zh) |
CN (1) | CN1110557C (zh) |
AT (1) | ATE352617T1 (zh) |
BR (1) | BR9507618A (zh) |
CA (1) | CA2189657C (zh) |
DE (1) | DE69535375T2 (zh) |
DK (1) | DK0758383T3 (zh) |
ES (1) | ES2281899T3 (zh) |
IL (1) | IL113617A (zh) |
MX (1) | MX9605365A (zh) |
NO (1) | NO325828B1 (zh) |
PT (1) | PT758383E (zh) |
RU (1) | RU2178306C2 (zh) |
WO (1) | WO1995030750A2 (zh) |
ZA (1) | ZA953629B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176921A (zh) * | 2008-08-11 | 2011-09-07 | 梅达雷克斯股份有限公司 | 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途 |
CN107428836A (zh) * | 2015-02-03 | 2017-12-01 | 安奈普泰斯生物有限公司 | 针对淋巴细胞活化基因3(lag‑3)的抗体 |
CN104411723B (zh) * | 2012-07-02 | 2018-01-30 | 百时美施贵宝公司 | 结合淋巴细胞活化基因‑3(lag‑3)的抗体的优化及该抗体的用途 |
CN108366548A (zh) * | 2015-11-20 | 2018-08-03 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
CN110950966A (zh) * | 2019-12-13 | 2020-04-03 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU701375B2 (en) * | 1995-07-21 | 1999-01-28 | Institut Gustave Roussy | Methods for detecting, identifying, isolating, and selectively labelling and targeting Th1 lymphocytes by means of the LAG-3 protein |
ATE320488T1 (de) * | 1996-11-28 | 2006-04-15 | Roussy Inst Gustave | Mutanten des lag-3 proteins, ihre expression und verwendung |
PT941329E (pt) * | 1996-11-29 | 2004-11-30 | Applied Research Systems | Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3) |
EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6660843B1 (en) † | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6434012B2 (en) * | 2000-02-11 | 2002-08-13 | Tyco Electronics Logistics Ag | Circuit board interconnect |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
CA2476518A1 (en) * | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP2006523226A (ja) † | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | T細胞調節方法 |
FR2868781B1 (fr) * | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
LT3178849T (lt) | 2013-09-20 | 2019-06-10 | Bristol-Myers Squibb Company | Anti-lag-3 antikūnų ir anti-pd-1 antikūnų derinys, skirtas navikų gydymui |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
KR20240110004A (ko) | 2014-03-14 | 2024-07-12 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性tnfr家族相關性受體(gitr)抗體類及使用彼等之方法 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
EP3943098A3 (en) | 2015-07-16 | 2022-05-11 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
EP3331919A1 (en) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
SG11201804265XA (en) | 2015-12-02 | 2018-06-28 | Agenus Inc | Antibodies and methods of use thereof |
MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
CA3008244A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
CA3012833A1 (en) * | 2016-02-04 | 2017-08-10 | Trianni, Inc. | Enhanced production of immunoglobulins |
TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
DK3476399T3 (da) | 2016-06-23 | 2022-05-30 | Jiangsu Hengrui Medicine Co | Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
TWI784976B (zh) | 2016-10-13 | 2022-12-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗lag-3抗體及組成物 |
TW201829462A (zh) | 2016-11-02 | 2018-08-16 | 英商葛蘭素史克智慧財產(第二)有限公司 | 結合蛋白 |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
EA201992350A1 (ru) | 2017-04-05 | 2020-03-23 | Симфоген А/С | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 |
US11339218B2 (en) * | 2017-05-10 | 2022-05-24 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against LAG3 and uses thereof |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
CA3073733A1 (en) | 2017-08-30 | 2019-03-07 | Phanes Therapeutics, Inc. | Anti-lag-3 antibodies and uses thereof |
RU2771384C2 (ru) * | 2017-12-22 | 2022-05-04 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение |
EP3969040A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
CN115340606B (zh) * | 2019-05-31 | 2023-12-19 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE721983T1 (de) | 1988-01-22 | 2002-07-04 | Zymogenetics, Inc. | Verfahren zur herstellung von biologisch-aktive Dimerpeptiden |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
JPH06508501A (ja) * | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | B細胞上のcd28レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
-
1995
- 1995-05-05 KR KR1019960706281A patent/KR100257466B1/ko not_active IP Right Cessation
- 1995-05-05 DE DE69535375T patent/DE69535375T2/de not_active Expired - Lifetime
- 1995-05-05 DK DK95920125T patent/DK0758383T3/da active
- 1995-05-05 ES ES95920125T patent/ES2281899T3/es not_active Expired - Lifetime
- 1995-05-05 BR BR9507618A patent/BR9507618A/pt not_active IP Right Cessation
- 1995-05-05 WO PCT/FR1995/000593 patent/WO1995030750A2/fr active IP Right Grant
- 1995-05-05 ZA ZA953629A patent/ZA953629B/xx unknown
- 1995-05-05 IL IL113617A patent/IL113617A/en not_active IP Right Cessation
- 1995-05-05 MX MX9605365A patent/MX9605365A/es active IP Right Grant
- 1995-05-05 US US08/737,271 patent/US5955300A/en not_active Ceased
- 1995-05-05 US US09/931,103 patent/USRE38313E1/en not_active Expired - Lifetime
- 1995-05-05 CN CN95193718A patent/CN1110557C/zh not_active Expired - Lifetime
- 1995-05-05 JP JP52872995A patent/JP3700859B2/ja not_active Expired - Lifetime
- 1995-05-05 AT AT95920125T patent/ATE352617T1/de active
- 1995-05-05 RU RU96123299/14A patent/RU2178306C2/ru active
- 1995-05-05 CA CA002189657A patent/CA2189657C/fr not_active Expired - Lifetime
- 1995-05-05 EP EP95920125A patent/EP0758383B1/fr not_active Expired - Lifetime
- 1995-05-05 PT PT95920125T patent/PT758383E/pt unknown
-
1996
- 1996-11-04 NO NO19964650A patent/NO325828B1/no not_active IP Right Cessation
-
1998
- 1998-04-13 US US09/058,555 patent/US6143273A/en not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176921A (zh) * | 2008-08-11 | 2011-09-07 | 梅达雷克斯股份有限公司 | 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途 |
CN102176921B (zh) * | 2008-08-11 | 2014-05-07 | 梅达雷克斯有限责任公司 | 结合淋巴细胞活化基因3(lag-3)之人类抗体及其用途 |
CN104411723B (zh) * | 2012-07-02 | 2018-01-30 | 百时美施贵宝公司 | 结合淋巴细胞活化基因‑3(lag‑3)的抗体的优化及该抗体的用途 |
CN107428836A (zh) * | 2015-02-03 | 2017-12-01 | 安奈普泰斯生物有限公司 | 针对淋巴细胞活化基因3(lag‑3)的抗体 |
CN108366548A (zh) * | 2015-11-20 | 2018-08-03 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
US11102961B2 (en) | 2015-11-20 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
CN108366548B (zh) * | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
CN110950966A (zh) * | 2019-12-13 | 2020-04-03 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
Also Published As
Publication number | Publication date |
---|---|
NO964650L (no) | 1997-01-06 |
WO1995030750A3 (fr) | 1995-12-21 |
AU2570195A (en) | 1995-11-29 |
US5955300A (en) | 1999-09-21 |
DK0758383T3 (da) | 2007-05-29 |
DE69535375D1 (de) | 2007-03-15 |
US6143273A (en) | 2000-11-07 |
MX9605365A (es) | 1997-12-31 |
ZA953629B (en) | 1996-11-05 |
CA2189657A1 (fr) | 1995-11-16 |
NO325828B1 (no) | 2008-07-28 |
NO964650D0 (no) | 1996-11-04 |
DE69535375T2 (de) | 2007-11-08 |
ATE352617T1 (de) | 2007-02-15 |
KR970702917A (ko) | 1997-06-10 |
JP3700859B2 (ja) | 2005-09-28 |
KR100257466B1 (ko) | 2000-07-01 |
EP0758383A1 (fr) | 1997-02-19 |
BR9507618A (pt) | 1997-08-19 |
CN1110557C (zh) | 2003-06-04 |
AU708825B2 (en) | 1999-08-12 |
USRE38313E1 (en) | 2003-11-11 |
WO1995030750A2 (fr) | 1995-11-16 |
IL113617A (en) | 2007-09-20 |
RU2178306C2 (ru) | 2002-01-20 |
IL113617A0 (en) | 1995-08-31 |
CA2189657C (fr) | 2002-03-12 |
EP0758383B1 (fr) | 2007-01-24 |
JPH09508023A (ja) | 1997-08-19 |
PT758383E (pt) | 2007-05-31 |
ES2281899T3 (es) | 2007-10-01 |
WO1995030750A8 (fr) | 1999-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1110557C (zh) | Lag-3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 | |
CN1317301C (zh) | Il-2-和il-15-介导的t细胞应答的调节 | |
CN1291757C (zh) | 炎性肠疾病的治疗剂 | |
CN1192779A (zh) | 人b7.1和/或b7.2特异的猴源单克隆抗体灵长动物化形式,药用组合物 | |
CN1898262A (zh) | Il-7融合蛋白 | |
CN1439022A (zh) | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 | |
CN1477968A (zh) | 用可溶性ctla4分子治疗风湿性疾病的方法 | |
CN1342202A (zh) | 可溶性受体br43×2和应用方法 | |
CN1835977A (zh) | Cd20-结合多肽组合物 | |
CN1379815A (zh) | Baff受体(bcma),一种免疫调节剂 | |
CN1359302A (zh) | 治疗免疫性疾病的药用组合物 | |
CN1268645C (zh) | 含有抗-fc受体结合剂的治疗化合物 | |
CN1146442C (zh) | 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体 | |
CN1438894A (zh) | 通过阻断淋巴细胞信号和阻断lfa-1介导的粘附作用调节细胞介导的免疫应答的方法 | |
CN1346370A (zh) | 与免疫应答有关的新颖多肽 | |
CN1891714A (zh) | 单纯疱疹病毒进入介体的配体和使用方法 | |
CN1473854A (zh) | 用于治疗il4介导疾病的重组il4抗体 | |
CN1194000A (zh) | 增强保护性免疫应答的方法 | |
CN1272345C (zh) | 沉默型抗cd-28抗体及其应用 | |
CN101080420A (zh) | 胸腺特异性蛋白质 | |
CN1245534A (zh) | 哺乳动物细胞表面抗原及相关试剂 | |
CN1838965A (zh) | 用于癌症治疗的药品 | |
CN1360596A (zh) | 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法 | |
CN1832963A (zh) | 同种排斥反应的特异性抑制 | |
CN1315866A (zh) | 使用cd2-结合剂调节记忆效应t-细胞的方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: FORMER OWNER: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. Effective date: 20120803 Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: FORMER OWNER: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE SERONO LAB Effective date: 20120803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120803 Address after: French sedeke Co-patentee after: National Research Center for Medicine and Health Patentee after: Gustavus Institute Co-patentee after: Merck Serono S.A. Address before: French sedeke Co-patentee before: National Research Center for Medicine and Health Patentee before: Gustavus Institute Co-patentee before: LABORATOIRES SERONO S.A. Effective date of registration: 20120803 Address after: French sedeke Co-patentee after: National Research Center for Medicine and Health Patentee after: Gustavus Institute Co-patentee after: LABORATOIRES SERONO S.A. Address before: French sedeke Co-patentee before: National Research Center for Medicine and Health Patentee before: Gustavus Institute Co-patentee before: Alice Applied Research Systems Co.,Ltd. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150505 Granted publication date: 20030604 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 19970730 Assignee: Eddingpharm Investment Co.,Ltd. Assignor: Immutep Contract record no.: 2015990000163 Denomination of invention: LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody Granted publication date: 20030604 License type: Exclusive License Record date: 20150402 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |